CML Myeloid Blast Phase
Showing 1 - 25 of >10,000
Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -
Recruiting
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- +3 more
- based decitabine and olverembatinib(HQP1351)chemotherapy
-
Guanzhou, ChinaDepartment of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in
Recruiting
- Acute Biphenotypic Leukemia
- +13 more
- Cladribine
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 19, 2023
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- ABL001
- +2 more
-
Chicago, Illinois
- +5 more
Dec 27, 2021
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +4 more
- Eltrombopag Olamine
-
Houston, TexasM D Anderson Cancer Center
Jan 4, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 25, 2022
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Cladribine
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2022
Philadelphia Chromosome Positive CML Trial in Worldwide (imatinib mesylate)
Completed
- Philadelphia Chromosome Positive CML
- imatinib mesylate
-
Chicago, Illinois
- +9 more
Jun 3, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia Trial in Houston (Clofarabine 40mg/m^2, Idarubicin
Completed
- Acute Myeloid Leukemia
- +2 more
- Clofarabine 40mg/m^2
- +5 more
-
Houston, TexasUT MD Anderson Cancer Center
Dec 3, 2020
Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase
Terminated
- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- +3 more
- Axitinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2020
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Metabolic Alternation and Clinicohematological Characteristic in
Not yet recruiting
- CML, Chronic Phase
- Tyrosine kinase inhibitor
- (no location specified)
Nov 6, 2023
CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))
Recruiting
- CML, Chronic Phase
- CML, Accelerated Phase
- HS-10382(Part 1: Dose escalation)
- HS-10382(Part 2: Dose expansion)
-
Wuhan, Hubei, ChinaUnion Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023
Ponatinib in CML Patients in Chronic Phase
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Therapeutic drug monitoring
- Molecular Response
-
Cagliari, Italy
- +4 more
Nov 3, 2023
Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis Trial in
Completed
- Myelodysplastic Syndrome RAEB-I or RAEB-II
- +2 more
- GM-CSF secreting leukemia vaccine
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 28, 2022
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023
CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)
Recruiting
- CML
- Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
-
Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, ArgentinaFUNDALEU
Jun 29, 2023
Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,
Recruiting
- Philadelphia Chromosome
- +4 more
- Azacitidine
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jun 23, 2022
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- +3 more
- Asciminib
- Ascimininb + Nilotinib
-
Augusta, Georgia
- +1 more
Jul 14, 2022
Among CP-CML Participants Initiating Dasatinib inReal Life
Completed
- Chronic Myeloid Leukemia
- Non-Interventional
-
Paris, FranceLocal Institution
Jun 17, 2022
Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Nilotinib
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Mar 15, 2022
Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online
Recruiting
- Myeloproliferative Neoplasm
- +2 more
- Online Mindfulness Meditation
- Internet-Based Webinars
-
San Francisco, CaliforniaUniversity of California San Francisco
Aug 9, 2022
CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)
Not yet recruiting
- CML, Chronic Phase
-
Harbin, Heilongjiang, ChinaInstitute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022
Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)
Recruiting
- Chronic Myeloid Leukemia in Chronic Phase
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Jul 26, 2022